Satellos Bioscience Inc. MSLE
8.70
(0.01)
(0.11%)
as of 25 Sep
- Market cap
- $184.8M
- P/E
- 0.0×
Follow MSLE
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(89.74%) | (66.37%) | (50.74%) | (70.45%) | |
| (79.73%) | (60.20%) | (47.66%) | (64.76%) | ||
ROIC |
0.00% | (22,347.13%) | (2,495.26%) | 0.00% | |
Return on Tangible Assets |
(64.78%) | (89.52%) | (40.33%) | (57.77%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.55) | (1.62) | (1.40) | (1.39) | |
Free Cash Flow |
(21.56) | (23.60) | (25.82) | (29.01) | |
Capital Expenditures |
(0.01) | (0.01) | (0.01) | (0.01) | |
Piotroski F-Score |
2.00 | 1.00 | 3.00 | 2.00 | |
| Other line items | |||||
Cash ROIC |
(31.41%) | (42.52%) | (18.36%) | (23.82%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.01 | 0.01 | 0.01 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.98 | 0.95 | 0.91 | 0.84 | |
Depreciation/Fixed assets |
2.17 | 0.80 | 0.50 | 0.71 | |
Capex/Depreciation |
(0.46) | (1.50) | (2.50) | (1.40) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.55) | (1.62) | (1.40) | (1.39) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates